Oxathiolane and Dioxolane Nucleosides: Synthesis and Antiviral Activity

Antiviral Nucleosides: Chiral Synthesis and Chemotherapy

Volumn , Issue , 2003, Pages 191-258

  Gumina, Giuseppe ^a   Cooperwood, John S ^a   Chu, Chung K ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34250004779     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1016/B978-044451319-9/50003-8     Document Type: Chapter

References (151)

1. Mitsuya H., Weinhold K.J., Furman P.A., St Clair M.H., Lehrman S.N., Gallo R.C., Bolognesi D., Barry D.W., Broder S. 3'-Azido-3'-deoxythymidine (BW A509U)-An antiviral agent that inhibits the infectivity and cytopathic effect of human lymphotropic-T virus type III lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA 1985, 82:7096-7100.
2. Mitsuya H., Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc. Natl. Acad. Sci. USA 1986, 83:1911-1915.
3. Lin T.-S., Schinazi R.F., Prusoff W.H. Potent and selective in vitro activity of 3'-deoxythymidine-2'-ene (3'-deoxy-2',3'-didehydrothymine) against human immunodeficiency virus. Biochem. Pharmacol. 1987, 36:2713-2718.
4. Riddler S.A., Anderson R.E., Mellors J.W. Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythimidine, D4T). Antiviral Res. 1995, 27:189-203.
5. Schinazi R.F., Chu C.K., Peck A., McMillan A., Mathis S., Cannon D., Jeong L.S., Beach J.W., Choi W.B., Yeola S., Liotta D.C. Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type I in human lymphocytes. Antimicrob. Agents Chemother. 1992, 36:672-676.
6. Dobkin J.F. Abacavir enters the clinic. Infect. Med. 1999, 16:7.
7. Daluge S.M., Good S.S., Faletto M.B., Miller W.H., St Clair M.H., Boone L.R., Tisdale M., Parry N.R., Reardon J.E., Dornsife R.E., Averett D.R., Krenitsky T.A. 1592U89. A novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 1997, 41:1082-1093.
8. Balzarini J., Aquaro S., Perno C.-F., Witvrouw M., Holy A., De Clercq E. Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochem. Biophys. Res. Comm. 1996, 219:337-341.
9. th International Conference on AIDS 1989, T.C.O.1.
10. Choi W.B., Wilson L.J., Yeola S., Liotta D.C. In situ complexation directs the stereochemistry of N-glycosylation in the synthesis of oxathiolanyl and dioxolanyl nucleoside analogs. J. Am. Chem. Soc. 1991, 113:9377-9379.
11. Chu C.K., Beach J.W., Jeong L.S., Choi B.G., Comer F.I., Alves A.J., Schinazi R.F. Enantiomeric synthesis of (+)-BCH-189 [(+)-(2S,5R)-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine] from d-mannose and its anti-HIV activity. J. Org. Chem. 1991, 56:6503-6505.
12. Jeong L.S., Alves A.J., Carrigan S.W., Kim H.O., Beach J.W., Chu C.K. An efficient synthesis of enantiomerically pure (+)-(2S,5R)-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-cytosine [(+)-BCH-189] from d-galactose. Tetrahedron Lett. 1992, 33:595-598.
13. Jeong L.S., Schinazi R.F., Beach J.W., Kim H.O., Shanmuganathan K., Nampalli S., Chun M.W., Chung W.K., Choi B.G., Chu C.K. Structure-activity relationships of β-d-(2S,5R)- and α-d-(2S,5S)-1,3-oxathiolanyl nucleosides as potential anti-HIV agents. J. Med. Chem. 1993, 36:2627-2638.
14. Beach J.W., Jeong L.S., Alves A.J., Pohl D., Kim H.O., Chang C.-N., Doong S.-L., Schinazi R.F., Cheng Y.-C., Chu C.K. Synthesis of enantiomerically pure 2'R,5'S-(-)-[2-(hydroxymethyl)-oxathiolan-5-yl]cytosine as a potent antiviral agent against hepatitis B virus (HBV) and human immunodeficiency virus (HIV). J. Org. Chem. 1992, 57:2217-2219.
15. Jeong L.S., Schinazi R.F., Beach J.W., Kim H.O., Nampalli S., Shanmuganathan K., Alves A.J., McMillan A., Chu C.K., Mathis R. Asymmetric synthesis and biological evaluation of β-l-(2R,5S)-and α-l-(2R,5R)-1,3 oxathiolane-pyrimidine and-purine nucleosides as potential anti-HIV agents. J. Med. Chem. 1993, 36:181-195.
16. Humber D.C., Jones M.F., Payne J.J., Ramsay M.V.J., Zacharie B., Jin H., Siddiqui M.A., Evans C.A., Tse H.L.A., Mansour T.S. Expeditious preparation of (-)-2'-deoxy-3'-thiacytidine (3TC). Tetrahedron Lett. 1992, 32:4625-4628.
17. Jin H., Siddiqui M.A., Evans C.A., Tse H.L.A., Mansour T.S. Diastereoselective synthesis of the potent antiviral agent (-)-2'-deoxy-3'-thiacytidine and its enantiomer. J. Org. Chem. 1995, 60:2621-2623.
18. Hoong L.K., Strange L.E., Liotta D.C. Enzyme-mediated enantioselective preparation of pure enantiomers of the antiviral agent 2',3'-dideoxy-5-fluoro-3'-thiacytidine (FTC) and related compounds. J. Org. Chem. 1992, 57:5563-5565.
19. TM). Tetrahedron Lett 1995, 36:6961-6964.
20. Djerassi C., Gorman M., Markley F.X., Oldenberg E.B. Studies in organic sulfur compounds. 7. Lithium aluminum hydride reduction of xanthates to mercaptans-synthesis of substituted betamercaptoethanols. J. Am. Chem. Soc. 1955, 77:568-571.
21. Mori K., Nakamura Y. Thiols and sulfides from xanthogenic acid ester. J. Org. Chem. 1969, 34:4170-4172.
22. Drescher M., Li Y.F., Hammerschmidt F. Enzymes in organic chemistry. 2. Lipase-catalyzed hydrolysis of 1-acyloxy-2-arylethylphosphonates and synthesis of phosphonic acid analogs of l-phenylalanine and l-tyrosine. Tetrahedron 1995, 51:4933-4946.
23. TM). Tetrahedron Asymmetry 1995, 6:393-396.
24. Mahmoudian M., Baines B.S., Drake C.S., Hale R.S., Jones P., Piercery J.E., Montgomery D.S., Purvis I.J., Storer R., Dawson M.J., Lawrence G.C. Enzymatic production of optically pure (2'R-cis)-2'-deoxy-3'-thiacytidine (3TC, lamivudine): a potent anti-HIV agent. Enzym. Microb. Technol. 1993, 15:749-755.
25. Gilbert B.E., Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob. Agents Chemother. 1986, 30:201-205.
26. Faury P., Camplo M., Charvet A.S., Chermann J.C., Kraus J.L. Synthesis of tetrazole oxathiolane nucleoside analogs and their evaluation as HIV-1 antiviral agents. Nucleosides Nucleotides 1992, 11:1481-1488.
27. Belleau B., Brasili L., Chan L., Di Marco M.P., Zacharie B., Nguyen-Ba N., Jenkinson H.J., Coates J.A.V., Cameron J.M. A novel class of 1,3-oxathiolane nucleoside analogs having potent anti-HIV activity. Bioorg. Med. Chem. Lett. 1993, 3:1723-1728.
28. Bednarski K., Dixit D.M., Wang W., Evans C.A., Jin H.L., Yuen L., Mansour T.S., Knight D.J., Walcott S., Coates J.A.V. 5'-(E)-(2″-bromovinyl)uracil 1,3-dioxolanes and 1,3-oxathiolanes as potential antiherpetic agents. Abstr. Papers Am. Chem. Soc. 1994, MEDI 024.
29. Jones A.S., Rahim S.G., Verhelst G., Walker R.T. Nucleic Acid Chemistry, Improved and New Synthetic Procedures, Methods and Techniques, Part 3 1986, 61-64. John Wiley and Sons, Inc., New York. L.B. Townsend, R.S. Tipson (Eds.).
30. Mansour T.S., Jin H.L., Wang W., Dixit D.M., Evans C.A., Tse H.L.A., Belleau B., Gillard J.W., Hooker E.U., Ashman C., Cammack N., Salomon H., Belmonte A.R., Wainberg M.A. Structureactivity relationships among a new class of antiviral heterosubstituted 2',3'-dideoxynucleoside analogs. Nucleosides Nucleotides 1995, 14:627-635.
31. Siddiqui M.A., Jin H.L., Evans C.A., Di Marco M.P., Tse H.L.A., Mansour T.S. (1'R,2'S,5'R)-Menthyl-(5R)-acetox-1,3-oxathiolan-(2R)-carboxylate-Synthesis and isomeric purity determination by HPLC. Chirality 1994, 6:156-160.
32. Wang W., Jin H.L., Mansour T.S. Synthesis of optically active 2',3'-dideoxy-3'-oxa-4'-thioribonucleoside analogs by transposition of a leaving group on chiral oxathiolanes via a reductive-oxidative process. Tetrahedron Lett. 1994, 35:4739-4742.
33. Mansour T.S., Jin H., Wang W., Hooker E.U., Ashman C., Cammack N., Salomon H., Belmonte A.R., Wainberg M.A. Anti-human immunodeficiency virus and anti-hepatitis B virus activities and toxicities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine and their 5-fluoro analogs in vitro. J. Med. Chem. 1995, 38:1-4.
34. 4-(N-formylpeptide)-2',3'-dideoxy-3'-thiacytidine as anti-HIV prodrug. Nucleosides Nucleotides 1993, 12:631-641.
35. Kraus J.L. New phosphonate analogs of 3'-thia-2',3'-dideoxycytidine (BCH-189)-Synthesis and anti-HIV evaluation. Nucleosides Nucleotides 1993, 12:157-162.
36. Storer R., Clemens I.R., Lamont B., Noble S.A., Williamson C., Belleau B. The resolution and absolute stereochemistry of the enantiomers of cis-1,2-hydroxymethyl-1,3-oxathiolan-5-yl-cytosine BCH-189: equipotent anti-HIV agents. Nucleotides Nucleotides 1993, 12:225-236.
37. Nokami J., Ryokume K., Inada J. Synthesis of 1,3-oxathiolane derivatives as novel precursors of 2'3'-dideoxy-3'-oxa-4'-thioribonucleosides. Tetrahedron Lett. 1995, 36:6099-6100.
38. Chao Q., Nair V. Synthesis and antiviral evaluation of 4'-hydroxymethyl-2',3'-dideoxy-3'-thianucleosides and their cyclic monophosphates. Bioorg. Med. Chem. Lett. 1997, 7:1199-2002.
39. Chang C.-N., Doong S.-L., Zhou J.H., Beach J.W., Jeong L.S., Chu C.K., Tsai C.H., Cheng Y.-C. Deoxycytidine deamination-resistant stereoisomer is the active form of (-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication. J. Biol. Chem. 1992, 267:13938-13942.
40. Choi W.B., Yeola S., Liotta D.C., Schinazi R.F., Painter G.R., Davis M., St.Clair M., Furman P.A. Synthesis, anti-human immunodeficiency virus, and anti-hepatitis B virus activity of pyrimidine oxathiolane nucleosides. Bioorg. Med. Chem. Lett. 1993, 3:693-696.
41. Sommadossi J.P., Schinazi R.F., Chu C.K., Xie M.Y. Comparison of cytotoxicity of the (-)-enantiomer and (+)-enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells. Biochem. Pharmacol. 1992, 44:1921-1925.
42. Parker W.B., Cheng Y.-C. Mitochondrial toxicity of antiviral nucleoside analogs. J. NIH Res. 1994, 6:57-61.
43. Cui L., Locatelli L., Xie M.Y., Sommadossi J.P. Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells. J. Pharmacol. Exp. Ther. 1997, 280:1228-1234.
44. Cammack N., Rouse P., Marr C.L.P., Reid P.J., Boehme R.E., Coates J.A.V., Penn C.R., Cameron J.M. Cellular metabolism of (-) enantiomeric 2'-deoxy-3'-thiacytidine. Biochem. Pharmacol. 1992, 43:2059-2064.
45. Coates J.A.V., Cammack N., Jenkinson H.J., Jowett A.J., Jowett M.I., Pearson B.A., Penn C.R., Rouse P.L., Viner K.C., Cameron J.M. (-)-2'-Deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob. Agents Chemother. 1992, 36:733-739.
46. Hart G.J., Orr D.C., Penn C.R., Figueiredo H.T., Gray N.M., Boehme R.E., Cameron J.M. Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerase α, β, and γ. Antimicrob. Agents Chemother. 1992, 36:1688-1694.
47. Zhu Y.L., Dutschman G.E., Liu S.H., Bridges E.G., Cheng Y.-C. Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydroβ-L(-)-5-fluorocytidine. Antimicrob. Agents Chemother. 1998, 42:1805-1810.
48. Lisignoli G., Monaco M.C.G., De Grassi A., Toneguzzi S., Ricchi E., Costigliola P., Facchini A. In vitro immunotoxicity of 2'-deoxy-3'-thiacytidine, a new anti-HIV agent. Clin. Exp. Immunol. 1993, 92:455-459.
49. Van Leeuwen R., Lange J.M.A., Hussey E.K., Donn K.H., Hall S.T., Harker A.J., Jonker P., Danner S.A. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection-A phase I study. AIDS 1992, 6:1471-1475.
50. Beach J.W. Chemotherapeutic agents for human immunodeficiency virus infection: Mechanism of action, pharmacokinetics, metabolism and adverse reactions. Clin. Ther. 1998, 20:2-25.
51. Heald A.E., Hsyu P.H., Yuen G.J., Robinson P., Mydlow P., Bartlett J.A. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob. Agents Chemother. 1996, 40:1514-1519.
52. Epivir product information 1996, Glaxo Wellcome Inc., Research Triangle Park, NC.
53. Rajagopalan P., Boudinot F.D., Chu C.K., Tennant B.C., Baldwin B.H., Schinazi R.F. Pharmacokinetics of (-)-2'-3'-dideoxy-3'-thiacytidine in woodchucks. Antimicrob. Agents Chemother. 1996, 40:642-645.
54. Johnson M.A., Moore K.H.P., Yuen G.J., Bye A., Pakes G.E. Clinical pharmacokinetics of lamivudine. Clin. Pharmacok. 1999, 36:41-66.
55. Severini A., Liu X.-Y., Wilson J.S., Tyrrell D.L.J. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)β-l-2',3'-dideoxy-3'-thiacytidine. Antimicrob. Agents Chemother. 1995, 39:1430-1435.
56. Miller R.H., Robinson W.S. Common evolutionary origin of hepatitis B virus and retroviruses. Proc. Natl. Acad. Sci. USA 1986, 83:2531-2535.
57. Gosselin G., Schinazi R.F., Sommadossi J.P., Mathé C., Bergogne M.C., Aubertin A.M., Kirn A., Imbach J.-L. Anti-human immunodeficiency virus activities of the β-L enantiomer of 2',3'-dideoxycytidine and its-5-fluoro derivative in vitro. Antimicrob. Agents Chemother. 1994, 38:1292-1297.
58. Schinazi R.F., Gosselin G., Faraj A., Korba B.E., Liotta D.C., Chu C.K., Mathé C., Imbach J.-L., Sommadossi J.-P. Pure nucleoside enantiomers of β-2',3'-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro. Antimicrob. Agents Chemother. 1994, 38:2172-2174.
59. Lee B., Luo W.X., Suzuki S., Robins M.J., Tyrrell D.L.J. In vitro and in vivo comparison of the abilities of purine and pyridime 2',3'-dideoxynucleosides to inhibit duck hepadnavirus. Antimicrob. Agents Chemother. 1989, 33:336-339.
60. Lai C.L., Chein R.N., Leung N.W.Y., Chang T.T., Guan R., Tai D.I., Ng K.Y., Wu P.C., Dent J.C., Barber J., Stephenson S.L., Fraser G. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 1998, 339:61-68.
61. Tisdale M., Kemp S.D., Parry N.R., Larder B.A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 1993, 90:5653-5656.
62. Wainberg M.A., Drosopoulos W.C., Salomon H., Hsu M., Borkow G., Parniak M.A., Gu Z.X., Song Q.B., Manne J., Islam S., Castriota G., Prasad V.R. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996, 271:1282-1285.
63. Fu L., Cheng Y.-C. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem. Pharmacol. 1998, 55:1567-1572.
64. Stuyver L.J., Locarnini S.A., Lok A., Richman D.D., Carman W.F., Diesntag J.L., Schinazi R.F. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001, 33:751-757.
65. Gao Q., Gu Z.H., Hiscott J., Dionne G., Wainberg M.A. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob. Agents Chemother. 1993, 37:130-133.
66. Rusconi S., De Pasquale M.P., Milazzo L., Bulgheroni E., Cittero P., Kurtagic S., D'Arminio-Monforte A., Galli M. In vitro effects of continuous pressure with zidovudine (ZDV) and lamivudine on aZDV-resistant HIV-1 isolate. AIDS 1997, 11:1406-1410.
67. Keulen W., Back N.K., Van Wijk A., Boucher C.A.B., Berkhout B. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 1997, 71:3346-3350.
68. Wainberg M.A., Salomon H., Gu Z, Montaner J.S.G., Cooley T.P., McCaffrey R., Ruedy J., Hirst H.M., Cammack N., Cameron J., Nicholson W. Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 1995, 9:351-357.
69. Mathez D., Schinazi R.F., Liotta D.C., Leibowitch J. Infectious amplification of wild-type human immunodeficiency virus from patients lymphocytes and modulation by reverse transcriptase inhibitors in vitro. Antimicrob. Agents Chemother. 1993, 37:2206-2211.
70. Gu Z., Gao Q., Faust E.A., Wainberg M.A. Possible involvement of cell-fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC. J. Gen. Virol. 1995, 76:2601-2605.
71. García Lerma J.G., Schinazi R.F., Juoadawlkis A.S., Soriano V., Lin Y.L., Tatti K., Rimland D., Folks T.M., Heneine W. A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC). Antimicrob. Agents Chemother. 1999, 43:264-270.
72. Ladner S.K., Miller T.J., King R.W. The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2'-deoxy-3'-thiacytidine and a reduced ability to synthesize viral DNA. Antimicrob. Agents Chemother. 1998, 42:2128-2131.
73. Fujioka S., Shimomura H., Fujio K., Ikeda F., Miyake M., Ishii Y., Itoh M., Sakaguchi K., Tsuji T. Two cases of chronic hepatitis B with emergence of lamivudine-resistant virus during long-term therapy. Hepatol. Res. 1999, 13:97-104.
74. Miller M.D., Anton K.E., Mulato A.S., Lamy P.D., Cherrington J.M. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reserve transcriptase shown increased susceptibility to adefovir and decreased replication capability in vitro. J. Infect. Dis. 1999, 179:92-100.
75. Bartlett J.A., Benoit S.L., Johnson V.A., Quinn J.B., Sepulveda G.E., Ehmann W.C., Tsoukas C., Fallon M.A., Self P.L., Rubin M. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. Ann. Intern. Med. 1996, 125:161-172.
76. Staszewski S., Loveday C., Picazo J.J., Dellamonica P., Skinhoj P., Johnson M.A., Danner S.A., Harrigan P.R., Hill A.M., Verity L., McDade H. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients-A randomized controlled comparison with zidovudine monotherapy. JAMA 1996, 276:111-117.
77. th Ed.
78. Eron J.J., Benoit S.L., Jemsek J., MacArthur R.D., Santana J., Quinn J.B., Kuritzkes D.R., Fallon M.A., Rubin M. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimiter. N. Engl. J. Med. 1995, 333:1662-1669.
79. Katlama C., Ingrand D., Loveday C., Clumeck N., Mallolas J., Staszewski S., Johnson M., Hill A.M., Pearce G., MaDade H. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients-A randomzied controlled comparison with zidovudine monotherapy. JAMA 1996, 276:118-125.
80. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Gonzalez C., McMahon D., Richman D.D., Valentine F.T., Jonas L., Meibohm A., Emini E.A., Chodakewitz J.A. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl J. Med 1997, 337:734-739.
81. Hammer S.M., Squires K.E., Hughes M.D., Grimes J.M., Demeter L.M., Currier J.S., Eron J.J., Feinberg J.E., Balfour H.H., Dayton L.R., Chodakewitz J.A., Fischl M.A. A controlled trial of two nucleoside analogs plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 1997, 337:725-733.
82. Staszewski S., Miller V., Rehmet S., Stark T., De Cree J., De Brabander M., Peeters M., Andries K., Moeremens M., De Raemaeker M., Pearce G., Van Den Broeck R., Verbiest W., Stoffels P. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS 1996, 10:F1-F7.
83. nd National Conference on Human Retroviruses and Related Infections 1995, LB6A.
84. Kuritzkes D.R., Quinn J.B., Benoit S.L., Shugarts D.L., Griffin A., Bakhtiari M., Poticha D., Eron J.J., Fallon M.A., Rubin M. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996, 10:975-981.
85. Larder B.a., Kemp S.D., Harrigan P.R. Potential mechanisms for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
86. Veal G.J., Hoggard P.G., Barry M.G., Khoo S., Back D.J. Interaction between lamivudine (3TC) and other nucleoside analogs for intracellular phosphorylation. AIDS 1996, 10:546-548.
87. Foudraine N.A., DeJong J.J., Weverling G.J., Van Benthem B.H.B., Maas J., Keet I.P.M., Jurriaans S., Roos M.T.L., Vandermeulen K., De Wolf F., Lange J.M.A. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine. AIDS 1998, 12:1513-1519.
88. Havlir D.V., Lange J.M.A. New antiretrovirals and new combinations. AIDS 1998, 12:S165-S174.
89. Foudraine N.A., Hoetelmans R., Lange J.M.A., De Wolf F., Van Benthem B.H.B., Mass J.J., Portegies P. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998, 351:1547-1551.
90. rd Conference on retroviruses and opportunistic infections 1996.
91. Patick A.K., Boritzki T.J., Bloom L.A. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro. Antimicrob. Agents Chemother. 1997, 41:2159-2164.
92. Landers M.B., Fraser V.J. Antiviral chemoprophylaxis after occupational exposure to human immunodeficiency virus: Why, when, where, and what. Am. J. Ophthal. 1997, 124:234-239.
93. Notermans D.W., Jurriaans S., DeWolf F., Foudraine N.A., DeJong J.J., Cavert W., Schuwirth C.M., Kauffmann R.H., Meenhorst P.L., McDade H., Goodwin C., Leonard J.M., Goudsmit J., Danner S.A. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. AIDS 1998, 12:167-173.
94. Wong J.K., Gunthard H.F., Havlir D.V., Zhang Z.Q., Haase A.T., Ignacio C.C., Kwok S., Emini E., Richman D.D. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc. Natl. Acad. Sci. USA 1997, 94:12574-12579.
95. Smith R.A., Remington K.M., Preston B.D., Schinazi R.F., North T.W.A. A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)β-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine. J. Virol. 1998, 72:2335-2340.
96. Kemp S.D., Shi C., Bloor S., Harrigan P.R., Mellors J.W., Larder B.A. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and l-2',3'-dideoxy-3'-thiacytidine. J. Virol. 1998, 72:5093-5098.
97. Schinazi R.F., McMillan A., Cannon D., Mathis R., Lloyd R.M., Peck A., Sommadossi J.-P., St Clair M., Wilson J., Furman P.A., Painter G., Choi W.B., Liotta D.C. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine. Antimicrob. Agents Chemother. 1992, 36:2423-2431.
98. Rousseau F., Wang L.H., Delehanty J., Hulett L., McCreedy B., Sommadossi J.-P., Barry D.W. Intracellular FTC-triphosphate levels correlate with the clinical antiviral activity of FTC. AIDS 1998, 12(Suppl. 4):OP75.
99. Wilson J.E., Martin J.L., Borroto-Esoda K., Hopkins S., Painter G., Liotta D.C., Furman P.A. The 5'-triphosphates of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine equally inhibit human immunodeficiency virus type 1 reverse transriptase. Antimicrob. Agents Chemother. 1993, 37:1720-1722.
100. Shewach D.S., Liotta D.C., Schinazi R.F. Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2'-deoxycytidine kinase. Biochem. Pharmacol. 1993, 45:1540-1543.
101. Cui L.X., Schinazi R.F., Gosselin G., Imbach J.-L., Chu C.K., Rando R.F., Revankar G.R., Sommadossi J.-P. Effect of beta-enantiomeric and recemic nucleoside analogs on mitochondrial functions in HepG2 cells-Implications for predicting drug hepatoxicity. Biochem. Pharmacol. 1996, 52:1577-1584.
102. Frick L.W., Lambe C.U., St John L., Taylor L.C., Nelson D.J. Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R, 5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl) -1,3-oxathiolan-5-yl]cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. Antimicrob, Agents Chemother. 1994, 38:2722-2729.
103. Schinazi R.F., Boudinot F.D., Ibrahim S.S., Manning C., McClure H.M., Liotta D.C. Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys. Antimicrob. Agents Chemother. 1992, 36:2432-2438.
104. Furman P.A., Davis M., Liotta D.C., Paff M., Frick L.W., Nelson D.J., Dornsife R.E., Wyrster J.A., Wilson L.J., Fyfe J.A., Tuttle J.V., Miller W.H., Condreay L., Averett D.R., Schinazi R.F., Painter G.R. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl) -1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 1992, 36:2686-2692.
105. Condreay L.D., Jansen R.W., Powdrill T.F., Johnson L.C., Selleseth D.W., Paff M.T., Daluge S.M., Painter G.R., Furman P.A., Ellis M.N., Averett D.R. Evaluation of the potent anti-hepatitis B virus agent (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model. Antimicrob. Agents Chemother. 1994, 38:616-619.
106. Fourel I., Cullen J.M., Saputelli J., Aldrich C.E., Schaffer P., Averett D.R., Pugh J., Mason W.S. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J. Virol. 1994, 68:8321-8330.
107. Cullen J.M., Smith S.L., Davis M.G., Dunn S.E., Botteron C., Cecchi A., Linsey D., Linzey D., Frick L., Paff M.T., Goulding A., Biron K. In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks. Antimicrob. Agents Chemother. 1997, 41:2076-2082.
108. Gish R.G., Leung N.W.Y., Wright T.L., Trinh H., Lang W., Kessler H.A., Fang L., Wang L.H., Delehanty J., Rigney A., Mondou E., Snow A., Rousseau F. Dose range study of pharmacokinetics safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob. Agents Chemother. 2002, 46:1734-1740.
109. Smith R.A., Remington K.M., Lloyd R.M., Schinazi R.F., North T.W. A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides. J. Virol. 1997, 71:2357-2362.
110. Bednarski K., Dixit D.M., Wang W., Evans C.A., Jin H., Yuen L., Mansour T.S. Inhibitory activities of herpes simplex viruses type 1 and 2 and human cytomegalovirus by stereoisomers of 2'-deoxy-3'-oxa-5-(E)-(2- bromovinyl)uridines and their 4'-thioanalogs. Bioorg. Med. Chem. Lett. 1994, 4:2667-2672.
111. De Muys J.-M., Gourdeau H., Nguyen-Ba N., Taylor D.L., Ahmed P.S., Mansour T., Locas C., Richard N., Wainberg M.A., Rando R.F. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine. Antimicrob. Agents Chemother. 1999, 43:1835-1844.
112. Norbeck D.W., Spanton S., Broder S., Mitsuya H. (±)-Dioxolane-T (±)-1-[(2β, 4β)-2-hydroxymethyl-4-dioxolanylthymine]. A new 2',3'-dideoxy nucleoside prototype with in vitro activity against HIV. Tetrahedron Lett. 1989, 30:6263-6266.
113. Wilson L.J., Choi W.B., Spurling T., Liotta D.C., Schinazi R.F., Cannon D., Painter G.R., St Clair M., Furman P.A. The synthesis and anti-HIV activity of pyrimidine dioxolanyl nucleosides. Bioorg. Med. Chem. Lett. 1993, 3:169-174.
114. Jin H.L., Tse H.L.A., Evans C.A., Mansour T.S., Beels C.M., Ravenscroft P., Humber D.C., Jones M.F., Payne J.J., Ramsay M.V.J. Unexpected effects of Lewis acids in the synthesis of optically pure 2'-deoxy-3'-oxacytidine nucleoside analogs. Tetrahedron: Asymmetry 1993, 4:211-214.
115. Kim H.O., Ahn S.K., Alves A.J., Beach J.W., Jeong L.S., Choi B.G., Van Roey P., Schinazi R.F., Chu C.K. Asymmetric synthesis of 1,3-dioxolane pyrimidine nucleosides and their anti-HIV activity. J. Med. Chem. 1992, 35:1987-1995.
116. Kim H.O., Schinazi R.F., Nampalli S., Shanmuganathan K., Cannon D.L., Alves A.J., Jeong L.S., Beach J.W., Chu C.K. 1,3-Dioxolanylpurine nucleosides (2R, 4R) and (2R, 4S) with selective anti-HIV-1 activity in human lymphocytes. J. Med. Chem. 1993, 36:30-37.
117. Kim H.O., Shanmuganathan K., Alves A.J., Shanmuganathan K., Cannon D.L., Alves A.J., Jeong L.S., Beach J.W., Chu C.K. Potent anti-HIV and anti-HBV activities of (-)-lβ-dioxolane-C and (+)-lβ-dioxolane-T and their asymmetric synthesis. Tetrahedron Lett. 1992, 33:6899-6902.
118. Kim H.O., Schinazi R.F., Shanmuganathan K., Jeong L.S., Beach J.W., Nampalli S., Cannon D.L., Chu C.K. lβ-(2S,4S)-and lα-(2S,4R)-Dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships. J. Med. Chem. 1993, 36:519-528.
119. Abushanab E., Bessodes M., Antonakis K. Practical enantiospecific syntheses of (+)-erythro-9-(2S-hydroxy-3R-nonyl)adenine. Tetrahedron Lett. 1984, 25:3841-3844.
120. Abushanab E., Vemishetti P., Leiby R.W., Singh H.K., Mikkilineni A.B., Wu D.C.J., Saibaba R., Panzica R.P. The chemistry of l-ascorbic and d-isoascorbic acids. 1. The preparation of chiral butanetriols and butanetetrols. J. Org. Chem. 1988, 53:2598-2602.
121. Belleau B., Evans C.A., Tse H.L.A., Jin H.L., Dixit D.M., Mansour T.S. Oxidative degradation of l-ascorbic acid acetals to 2',3'-dideoxy-3'-oxaribofuranosides-Synthesis of enantiomerically pure 2',3'- dideoxy-3'-oxacytidine stereoisomers as potential antiviral agents. Tetrahedron Lett. 1992, 33:6949-6952.
122. Belleau B., Dixit D.M., Ba N.N., Brown W.L., Gulini U., Laffeur D., Cameron J.M. Synthesis and anti-HIV activity of (±)-1,3-dioxolane nucleoside analogs and their enzymatic resolution. Abstr. Papers Am. Chem. Soc. 1992, 204:138.
123. Evans C.A., Dixit D.M., Siddiqui M.A., Jin H., Tse H.L.A., Cimpoia A., Bednarski K., Breining T., Mansour T.S. Divergent asymmetric syntheses of dioxolane nucleoside analogs. Tetrahedron: Asymmetry 1993, 4:2319-2322.
124. Siddiqui M.A., Brown W.L., Nguen-Ba N., Dixit D.M., Mansour T.S., Hooker E., Viner K.C., Cameron J.M. Antiviral optically pure dioxolane purine nucleosides analogs. Bioorg. Med. Chem. Lett. 1993, 3:1543-1546.
125. Efimtseva E.V., Mikhailov S.N., Meshkov S.V., Lönnberg H. Synthesis and physicochemical properties of dioxolane nucleoside analogs. Acta. Chem. Scand. 1992, 46:1122-1126.
126. Mikhailov S.N., Efimtseva E.V., Meshkov S.V., Kern E.R. Nucleoside analogs on the basis of 4(R), 5(R)-dihydroxymethyl-2-methyl-1,3-dioxolane. Nucleosides Nucleotides 1994, 13:615-623.
127. Efimtseva E.V., Mikhailov S.N., Victorova L.S., Rosovskaya T.A., Beabealashvilli R.S. Synthesis of dioxolane analogs of dideoxynucleotides and their substrate properties in DNA synthesis reactions. Nucleosides Nucleotides 1995, 14:727-729.
128. Du J., Qu F., Lee D., Newton M.G., Chu C.K. 1,3-Dioxolane C-nucleosides-Asymmetric synthesis of 4 stereoisomers of 2-[2-(hydroxymethyl)-1,3-dioxolan-5-yl]-1,3-thiazole-4-carboxamide. Tetrahedron Lett. 1995, 36:8167-8170.
129. Qu F., Hong J.H., Du J., Newton M.G., Chu C.K. Asymmetric synthesis of (2'R,4'R) and (2'S,4'S)-1,3-dioxolanyl triazole C-nucleosides. Tetrahedron 1999, 55:9073-9088.
130. Grove K.L., Guo X., Liu S.H., Kukhanova M., Chu C.K., Cheng C.-Y. β-l-(-)-Dioxolane cytidine (β-l-(-)-OddC) as a potent compound for the treatment of cancer. Nucleosides Nucleotides 1997, 16:1229-1233.
131. Grove K.L., Guo X., Liu S.H., Gao Z.L., Chu C.K., Cheng Y.-C. Anticancer activity of β-l-dioxolane cytidine, a novel nucleoside analog with the unnatural l-configuration. Cancer Res. 1995, 55:3008-3011.
132. Grove K.L., Cheng Y.-C. Uptake and metabolism of the new anticancer compound β-l-dioxolane cytidine in human prostate carcinoma DU-145 cells. Cancer Res. 1996, 56:4187-4191.
133. Moore M., Belanger K., Jolivet J., Baker S., Wainman N. NCIC CTG IND 103: A phase I and pharmacokinetic (PK) study of the novel l-nucleoside analog troxacitabine (BCH-4556) given every 21 days. Eur. J. Cancer 1999, 35:S284.
134. Schwartz P.M., Haggerty J.G., Cheng Y.-C. β-l-1,3-Dioxolane-cytidine: A novel nucleoside that inhibits proliferation and induces differentiation of keratinocytes in vitro. Skin Pharmacol. Applied. Skin Physiol. 1998, 11:207-213.
135. Mar E.C., Chu C.K., Lin J.C. Some nucleoside analogs with anti-human immunodeficiency virus activity inhibit replication of Epstein-Barr virus. Antiviral Res. 1995, 28:1-11.
136. Schinazi R.F., McClure H.M., Boudinot F.D., Xiang Y.J., Chu C.K. Development of (-)β-d-2,6-diaminopurine dioxolane as a potential antiviral agent. Antiviral Res. 1994, 23(suppl. 81).
137. Rajagopalan P., Boudinot F.D., Chu C.K., Tennant B.C., Baldwin B.H., Schinazi R.F. Pharmacokinetics of (-)β-d-2,6-diaminopurine dioxolane and its metabolite, dioxolane guanosine, in woodchucks (Marmota monax). Antimicrob. Agents Chemother. 1996, 7:65-70.
138. Chen H., Boudinot F.D., Chu C.K., McClure H.M., Schinazi R.F. Pharmacokinetics of (-)β-d-2-aminopurine dioxolane and (-)β-d-2-amino-6-chloropurine dioxolane and their antiviral metabolite (-)β-d-dioxolane guanine in rhesus monkeys. Antimicrob. Agents Chemother. 1996, 40:2332-2336.
139. Furman P.A., Jeffrey J., Kiefer L.L., Feng J.Y., Anderson K.S., Borroto-Esoda K., Hill E., Copeland W.C., Chu C.K., Sommadossi J.-P., Liberman I., Schinazi R.F., Painter G.R. Mechanism of action of 1β-d-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1β-d-dioxolane guanosine. Antimicrob. Agents Chemother. 2001, 45:158-165.
140. Gu Z., Wainberg M.A., Nguyen-Ba P., L'Heureux L., de Muys J.-M., Rando R.F. Anti-HIV activities of 1,3-dioxolane guanine and 2,6-diaminopurine dioxolane. Nucleosides Nucleotides 1999, 18:891-892.
141. th Conference on Retroviruses and Opportunistic Infections 2000, Abstr. 668.
142. Mewshaw J.P., Myrick F.T., Wakefield D.A.C.S., Hooper B.J., Harris J.L., McCreedy B., Borroto-Esoda K. Dioxolane guanosine, the active form of the prodrugs diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. J. Acquir. Immune Defic. Syndr. 2002, 29:11-20.
143. Ono S.K., Kato N., Shiratori Y., Kato J., Goto T., Schinazi R.F., Carrilho F.J., Omata M. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Inv. 2001, 107:449-455.
144. Chin R., Shaw T., Torresi J., Sozzi V., Trautwein C., Bock T., Manns M., Isom H., Furman P.A., Locarnini S. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)β-d-2,6-diaminopurine dioxolane and 2'-fluoro-5- methylβ-l-arabinofuranosyluracil. Antimicrob. Agents Chemother. 2001, 45:2495-2501.
145. Gu Z.X., Wainberg M.A., Nguyen-Ba N., L'Heureux L., de Muys J.M., Bowlin T.L., Rando R.F. Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogs against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob. Agents Chemother. 1999, 43:2376-2382.
146. Bazmi H.Z., Hammond J.L., Cavalcanti S.C.H., Chu C.K., Schinazi R.F., Mellors J.W. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)β-d-dioxolane-guanosine and suppress resistance to 3 '-azido-3'-deoxythymidine. Antimicr. Agents Chemother. 2000, 44:1783-1788.
147. Lin J.-S., Kira T., Gullen E., Choi Y., Qu F., Chu C.K., Cheng Y.-C. Structure-activity relationships of l-dioxolane uracil nucleosides as anti-Epstein Barr virus agents. J. Med. Chem. 1999, 42:2212-2217.
148. Kira T., Grill S.P., Dutschman G.E., Lin J.-S., Qu F., Choi Y., Chu C.K., Cheng Y.-C. Anti-Epstein-Barr virus (EBV) activity of -l-5-iododioxolane uracil is dependent on EBV thymidine kinase. Antimicrob. Agents Chemother. 2000, 44:3278-3284.
149. Choi Y., Li L., Grill S., Gullen E., Lee C.S., Gumina G., Cheng Y.-C., Chu C.K. Structure-activity relationships of (E)-5-(2-bromovinyl)uracil nucleosides and related analogs as anti-herpesvirus agents. J. Med. Chem. 2000, 43:2538-2546.
150. Li L., Dutschman G.E., Gullen E.A., Grill S.P., Choi Y., Chu C.K., Cheng Y.-C. Inhibition of the growth of varicella-zoster virus by lβ-5-bromovinyl-(2-hydroxymethyl)-1,3-dioxolanyluracil. 91th Annual Meeting of the American Association for Cancer Research, 2000, A22. American Association for Cancer Research, San Francisco, CA.
151. Li L., Dutschman G.E., Gullen E.A., Tsujii E., Grill S.P., Choi Y., Chu C.K., Cheng Y.-C. Metabolism and mode of inhibition of varicella-zoster virus by l-5-bromovinyl-(2-hydroxymethyl)-(1,3-dioxolanyl)uracil is dependent on viral thymidine kinase. Mol. Pharmacol. 2000, 58:1109-1114.